Even if the mortality rate in breast cancer (BC) has recently decreased, development of metastases and drug resistance are still challenges to successful systemic treatment. The epithelial-to-mesenchymal transition (EMT), as well as epigenetic dynamic modifications, plays a pivotal role in invasion, metastasis, and drug resistance. Here, we report that WDR5, the core subunit of histone H3 K4 methyltransferase complexes, is crucial in coordinating EMT and regulating epigenetic changes that drive metastasis. We show that silencing of WDR5 in BC up-regulates an epithelial signature in triple negative and luminal B like patients by transcriptional repression of mesenchymal genes and reduction of the metastatic properties of these cells. Moreover, we demonstrate that this regulation is mediated by inhibition of the TGFb signaling both at the transcriptional and posttranslational level, suggesting an active role of WDR5 in guiding tumor plasticity upon oncogenic insults, regardless of the pathological BC subtypes.
Introduction
Despite recent advances in BC treatment, women frequently develop resistance to many therapies and die of metastasis (Ginsburg, Bray et al., 2017) . Epithelial-to-mesenchymal transition (EMT) is a well-defined developmental program frequently adopted by tumor cells during the metastatic process to gain migratory ability and reach distant organs, losing epithelial cell adhesion and cell-cell contacts, while undergoing cell shape remodeling and cytoskeleton rearrangement (Christiansen & Rajasekaran, 2006 , Nieto, 2013 .
Concurrently, the expression of epithelial markers is inhibited, in favor of an increase in the expression of the mesenchymal genes (Thiery & Sleeman, 2006) . The epithelial and mesenchymal states represent two opposite cellular phenotypes that cells reach going through several intermediary phases (Grande, Sanchez-Laorden et al., 2015 , Jordan, Johnson et al., 2011 , Yu, Bardia et al., 2013 .
During EMT, changes in gene expression are crucial for the process to occur. Availability of appropriate transcription factors and degree of openness or closeness of the chromatin play a central role in determining changes in gene expression (Bedi, Mishra et al., 2014) .
Indeed, the EMT transcriptional program is tightly controlled by both DNA methylation (Cedar & Bergman, 2009 ) and post-translational histone regulation (Campos & Reinberg, 2009 ). Even if the epigenetic contribution to the process is not fully understood, several histone modifications are implicated in either inducing or repressing specific sets of EMT genes (Lee & Kong, 2016) . The core subunit of the COMPASS-like complex WD repeatcontaining protein 5 (WDR5) recognizes the histone H3 amino-terminal tail, thus enabling its methylation on Lys4 (H3K4) (Ford & Dingwall, 2015) . WDR5 has a pivotal role in tumor growth and proliferation (Carugo, Genovese et al., 2016 , Chen, Xie et al., 2015 , Mungamuri, Murk et al., 2013 , differentiation (Ang, Tsai et al., 2011 , Wang, Han et al., 2017 and metastasis (Lin, Wang et al., 2017 , Malek, Gajula et al., 2017 , Tan, Chen et al., 2017 , showing deregulated expression in different cancers , Chen et al., 2015 , Cui, Li et al., 2018 , Dai, Guo et al., 2015 , Ge, Song et al., 2016 , Wu, Diao et al., 2018b . Moreover, mesenchymal genes are marked with H3K4me3 by WDR5 in breast cancer upon hypoxia treatment (Wu, Tsai et al., 2011) , and in colorectal , prostate (Malek et al., 2017) , and lung 26 tumor cells. Despite its proven role in EMT, the causal role of WDR5 in cellular plasticity during EMT still remains elusive.
Transforming growth factor-b (TGFb) is a multifunctional cytokine involved in a plethora of events regulating EMT in the context of metastasis. Both canonical and non-canonical TGFb signaling are involved in the regulation of distinct processes as cytoskeleton organization, survival, cell migration and invasion (Micalizzi & Ford, 2009) . It has been reported that TGFb cooperates with other signaling pathways, as well as epigenetic regulators, in the induction of transcription factors, such as the SNAIL, ZEB and TWIST families, driving EMT (Cardenas, Zhao et al., 2016 , Chen, Lorton et al., 2017 .
Here, we demonstrate that WDR5 is directly involved in the epigenetic regulation of cellular plasticity in BC during EMT and that its inhibition reverts the mesenchymal phenotype mediated by the TGFb1 response.
Results

WDR5 promotes growth of human breast cancer and is a potential therapeutic target
In our previous study, we performed a loss of function shRNA screening in the MCF10DCIS.com (hereafter MCF10DCIS) BC cell line to identify epigenetic targets driving tumorigenesis (D'Alesio, . Since WDR5 was strongly depleted both in the in vivo and in vitro screens and it ranked as one of the best candidate in sustaining BC growth , we first validated its oncogenic role in MCF10DCIS cells.
Cells were transduced with two pooled shRNAs to silence WDR5 and a corresponding control (shLuc) (Appendix Fig. S1A ) and were either transplanted in NOD/SCID mice to assess in vivo tumor growth, or cultured to evaluate the in vitro proliferative ability. WDR5 silencing strongly reduced tumor growth in vivo (Fig. 1A) , as well as proliferation in vitro (Fig. 1B) , confirming that WDR5 is crucial in sustaining BC growth. Concordantly, we tested the efficacy of the WDR5 small molecule inhibitor, OICR-9429, already proven to be effective in leukemia, pancreatic and lung cancer cells , Grebien, Vedadi et al., 2015 . In vitro treatment of MFC10DCIS cells with OICR-9429 reduced clonogenicity (Fig. 1C) and proliferation ( Fig. 1D ) in a dose-dependent manner, similar to that observed by using shRNA.
In order to generate a reliable model to elucidate BC development and treatment opportunities, we created a bank of patient-derived xenografts (PDXs) obtained from liver and lung metastases of BC (MBC) patients who developed resistance to different lines of therapy (Appendix Table S1A ). We demonstrated that PDXs recapitulate the phenotypic and molecular features of the tumors (Appendix Table S1B ) and we used them as patient surrogates of the metastatic disease to investigate WDR5 expression. Since large evidence show the over-expression of WDR5 in diverse tumor types , Chen et al., 2015 , Cui et al., 2018 , Ge et al., 2016 , Wu et al., 2018b , we confirmed that WDR5 expression was significantly higher in MBC PDXs than in the normal mammary gland (Fig.   1E ).
Six PDXs, representing triple negative (TN) and luminal B like (LB) BC subtypes, were used for the in vivo studies. Two TN (MBC2 and MBC7) and 4 LB (MBC3, MBC22, MBC18 and MBC26) PDXs were independently transduced with two shRNAs WDR5-specific in pool or a corresponding control (shLuc) (Appendix Fig. S1B) . In parallel, we tested WDR5-silencing effects in highly aggressive TN (SUM149PTand MDAMB468) and LB (HCC1428 and ZR751) BC cell lines (Prat, Karginova et al., 2013) (Appendix Fig. S1C ). The reduction of WDR5 expression significantly inhibited tumor growth in MBC PDXs (Fig. 1F ) and in all tested cell lines (Appendix Fig. S1D ). In vitro proliferation was also significantly impaired by shWDR5 (Appendix Fig. S1E ), suggesting that WDR5 may be involved in tumorigenesis, independently of the BC subtypes.
WDR5 expression promotes breast cancer metastasization
Despite the fact that WDR5 has been reported to promote migration in vitro and metastasization in vivo in colon and prostate cancer cell lines (Malek et al., 2017 , its role in BC is still unproven. We therefore compared the metastatic ability of shLuc and shWDR5 MDA-MB-231 cells by performing functional assays both in vivo and in vitro. Cells were first transduced with the Luciferase gene and then with either the WDR5 shRNA or the neutral control (SCR) and transplanted in the 4 th mammary gland of NSG mice. Tumors were resected at the same volume in the control and WDR5-silenced groups (Appendix Fig. S2A ) and mice were weekly tested for metastasis formation by bioluminescence assay. MDA-MB-231 metastasized to lung and axillary lymph nodes in SCR ( Fig. 2A, upper panel) transplanted mice, while WDR5 silencing totally inhibited (3/5), or significantly reduced (2/5), the number and size of the metastatic foci ( Fig. 2A, lower panel), as confirmed by the histological staining of the metastatic organs (Appendix Fig.   S2B ).
Modified Boyden chamber assay consistently demonstrated that WDR5 silencing led to a substantial reduction of the MDA-MB-231 cell migration (Fig. 2B) , as well as in 6 MBC PDXs (Fig. 2C ) and in MCF10DCIS (Appendix Fig. S2C ) and the TN and LB cell lines (Appendix Fig. S2D ) mentioned above. Concordantly, wound healing assay (Appendix Fig. S2E , S2F), performed in shWDR5 MDA-MB-231 cells, displayed a significant impairment of cell migration, as well. Overall these data suggest that WDR5 impacts on the ability of BC cells to migrate and metastasize to distant organs, and that its over-expression may be predictive of metastatic disease. To this aim, we analyzed WDR5 expression and Metastasis Free Survival (MFS) in a NKI data set of 295 patients, showing that higher WDR5 expression was associated with worse MFS (Fig. 2D) , and that the prognostic role of WDR5 was independent of the hormonal and therapeutic status (Fig. 2E ).
WDR5 silencing inhibits EMT in breast cancer
The ability of BC cells to metastasize has been correlated with the acquisition of an EMT phenotype (Chaffer, San Juan et al., 2016) . Further, previous works suggested that WDR5 might regulate metastasis formation by inducing EMT in various cancers , Malek et al., 2017 , Wu, Xiang et al., 2018a . We tested whether WDR5 silencing could reduce the migratory ability of BC cells by directly inhibiting EMT. As maintenance of the epithelial phenotype requires the coordinated expression of a set of genes directly implicated in cell adhesion and cytoskeletal polarization, we evaluated the transcriptional profile of control (shLuc) and shWDR5-silenced PDXs cells (2 TN and 3 LB) by RNA-seq. For each PDX we performed pairwise analysis to identify differentially expressed genes (DEGs) (Fig. 3A) . In order to exclude individual specificities, possibly due to the intra-and inter-tumor heterogeneity of BC (Polyak, 2011) , we considered a Golden Gene Set (GGS) of 161 down-and 92 upregulated genes in common among at least 2 PDXs (Fig. 3B , Appendix Table S2 ). Gene Ontology (GO) analysis of GGS is shown in Figure 3C . Top ranking categories were related to cell polarization and adhesion, consistently reflecting changes in cell shape and cytoskeleton rearrangement that affect cell motility ( Fig. 3C and Appendix Table S2 ). The inhibition of migratory cell ability may be in part explained by down-regulation of MAPRE1, a master regulator of microtubules (Rovini, Gauthier et al., 2013) and SDCBP, related to polarized distribution of F-actin (Das, Pradhan et al., 2018) . Moreover, HSPA1B and PPME1 over-expression has been associated with poor survival of patients with ovarian, gastric and lung cancers (Jakobsson, Moen et al., 2015 , Li, Han et al., 2014 , suggesting that their down-modulation may reduce tumor progression. Concordantly, actin cytoskeleton rearrangements were detected in shLuc and shWDR5 MCF10DCIS cells.
Immunofluorescence analysis revealed that filamentous actin (F-actin) was assembled into actin stress fibers in control cells, while in shWDR5 cells F-actin predominantly organized in cortical bundles tightly associated with cell-cell adhesions (Fig. 3D) , reminiscent of an epithelial-like phenotype. We also investigated the adhesion properties of WDR5-silenced MCF10DCIS cells on a panel of extracellular matrices (collagen, laminin, fibronectin, matrigel), showing that cell adhesion is increased in shWDR5 cells both in term of cell number ( Fig.3E and Appendix Fig. S3A ) and cell spreading ( Fig.3E and Appendix Fig.   S3B ), thus suggesting a tighter cell anchoring to the matrix.
We further characterized the expression of epithelial and mesenchymal markers in MBC PDXs in response to WDR5 silencing. WDR5 knockdown increased protein levels of Ecadherin (CDH1), a prominent biomarker of the epithelial state, while reduced the mesenchymal marker Vimentin (VIM) (Fig. 3F ), suggesting that WDR5 may have a direct role in phenotype reversion. Moreover, the majority of genes acting as mesenchymal inducers or epithelial repressors, i.e. CDH2, TWIST1, SNAI1, SNAI2 and ZEB1, were transcriptionally down-modulated upon WDR5 silencing (Appendix Fig. S3C ). Since, the transition from a mesenchymal to an epithelial state with drug treatment can be used to enhance lethality and eradicate epithelial cells, as well as a strategy to sensitize cells to chemotherapy (Meidhof, Brabletz et al., 2015) , we used MCF10DCIS and MDA-MB-231 to test the effect of WDR5 inhibition on lethality and sensitization to paclitaxel (PTX). PTX administration, upon WDR5 silencing, significantly reduced MCF10DCIS cells viability after 72h of exposure with respect to WDR5-untreated cells (Appendix Fig. S3D ). Interestingly, MDA-MB-231, that showed higher resistance to PTX, displayed significantly enhanced cell death also at low PTX doses upon WDR5 silencing (Appendix Fig. S3E ).
Conversely, over-expression of WDR5 caused changes in cell morphology, leading to an elongated spindle shape of the cells (Appendix Fig. S4A ), accompanied by the induction of mesenchymal gene expression (Appendix Fig. S4B ), and increased tumorigenicity of MCF10DCIS cells in vivo (Appendix Fig. S4C ). Overall, these observations suggest that WDR5 regulates the EMT program at transcriptional level in breast cancer cells and that its silencing can inhibit the mesenchymal phenotype.
WDR5 mediates epigenetic regulation of EMT
The EMT program is governed by a series of complex epigenetic interactions of transcription factors with protein complexes, whose mechanisms of action in driving plasticity during transition is still debated (Skrypek, Goossens et al., 2017) . WDR5, as the core component of histone H3K4 methyltransferase complexes, is responsible of the methylation pattern of many EMT genes . We first analyzed WDR5 occupancy at the promoter regions of genes in MCF10DCIS cells by chromatin immunoprecipitation (ChIP) and sequencing. We found that around 80% (4413/5794) of the peaks were located proximal to the Transcription Start Sites (TSS) (± 3000 bp from TSS), confirming that WDR5 regulates its targets mainly at the promoter level (Fig. EV 1A) . KMT2A/MLL1 and ERBB2, already known interactors of WDR5 (Ford & Dingwall, 2015 , Mungamuri et al., 2013 , are among these genes, thus validating our analysis. We also showed that TGFb1, SMAD2 and SMAD3 and some members of the PI3K complex displayed a peak of WDR5 on their promoters, suggesting that WDR5 may be involved in multiple signaling regulation (Table EV 1 ). We performed additional RNAseq analysis in shLuc and shWDR5 MCF10DCIS cells, and we detected 1'315 down-and 919 up-regulated DEGs. Diverse epithelial identity genes, keratins, genes regulating tight junctions and focal adhesions, as well as cell-cell adhesion molecules were found upregulated ( Fig. EV 1B) . On the contrary, genes commonly involved in promoting mesenchymal phenotype and metastasis (i.e. TGFb1, FOXQ1, ERBB3, S100A14, KIF4, CCR1, HAS2, PAK1 and TIAM1) were down-regulated ( Fig. EV 1B) , thus suggesting that WDR5 knockdown may sustain an epithelial phenotype. We therefore assessed H3K4me3 intensity at the promoter level of the expressed genes (± 1'500 bp from TSS) ( Table EV 3) in MCF10DCIS cells, and we observed a global reduction of intensity in shWDR5 with respect to shLuc (P= 4.5E-9) (Fig. 4A ). Remarkably, a statistical significant reduction in H3K4me3 intensity was observed at the promoter of the down-regulated (P = 1.2E-15), but not of up-regulated genes ( Fig. 4A) , confirming that the main effects due to WDR5 knockdown were observed in the down-modulated genes and that H3K4me3 signals, which associate with active and poised TSS, correlated with WDR5-dependent gene expression.
We also determine level of H3K4me3 intensity at WDR5 peaks in the DEGs in MCF10DCIS cells. Among 907 hypo-methylated regions associated to gene promoters, 260 were found to show both differential expression and H3K4 trimethylation level (238 showed the same direction of alteration). Importantly, we detected 62 genes where WDR5 peaks are close to the TSS of the regulated genes ( Fig. EV 1C) . Among the top interesting ones we listed TGFb1 (Fig. 4B ), suggesting that WDR5 is essential for H3K4 methylation on TGFb1 promoter and may be prominent for its activation. On the other side, among 698 hypermethylated regions, 58 were also differentially expressed and 51 showed concordance in H3K4me3 increase. Only 5 out of 58 regions were directly bound by WDR5 (Fig. EV 1C) .
Interestingly, TGFb signaling scored as one of the most significantly enriched biological functions in MBC PDXs (Appendix Table S2 ). The modulation of TGFb-dependent pathways includes down-regulation of many oncogenes ( Fig. 4C ): (i) TGFbR2, as TGFb type II receptor sustains metastasis of high-grade BC tumors (Tang, Vu et al., 2003) ; (ii) FURIN, a proprotein convertase that promotes the malignant phenotype of cancer cells (Jaaks & Bernasconi, 2017) and stimulate BC invasion (Li, Chu et al., 2018) ; (iii) GCNT2, that modulates EMT by modification of E-cadherin glycosylation (Zhang, Meng et al., 2011);  (iv) PARD6, crucial for cell polarization (Mu, Zang et al., 2015) and (v) LTBP2, the Latent TGFb-Binding protein, whose knock down inhibits tumorigenesis in thyroid carcinomas (Wan, Peng et al., 2017) . Conversely, the tumor suppressor TGFbR3 was up-regulated in WDR5 silenced cells ( Fig. 4C and Appendix Table S2 ), consistent with its role in suppressing metastasis formation in clear-cell renal cell carcinoma (Nishida, Miyazono et al., 2018) . Finally, Ingenuity Pathway Analysis (IPA) confirmed that TGFb1 resulted the top-ranking among genes or complexes that regulate EMT in breast cancer (HDAC3, ERBB2, HIF1A, SMAD7) (Ingthorsson, Andersen et al., 2016 , Papageorgis, Lambert et al., 2010 , as well as to be involved in tumor progression and metastatic dissemination (i.e. PI3K, E2F4, VEGFA and STAT3) (Beshiri, Holmes et al., 2012 , Das et al., 2018 , Jang, Kim et al., 2017 . When transcriptomic profiles of the GGS of the PDXs and of the MCF10DCIS cells have been intersected, 99 down-regulated and 40 up-regulated genes were found in common (Fig. 4E) . In details, we found that 6 out of 17 genes included in the TGFb1-pathway have a role in sustaining cell migration in a number of cancer cells and were concordantly down-modulated in the majority of the MBC PDXs (Fig. 4F) , as well as in MCF10DCIS (Fig. EV 1D) . Interestingly, CEMIP (Cell Migration Inducing Hyaluronan Binding protein) expression regulates invasion and metastasis in colon cancer (Evensen, Li et al., 2015) , HSPA1B (Heat Shock 70kDa Protein 1B) in ovarian cancer (Jakobsson et al., 2015) , AIF1L (Allograft Inflammatory Factor 1 Like) determines cytoskeleton rearrangement (Lu, Ye et al., 2017) , and PNP (purine nucleoside phosphorylase) affects prostate cell migration (Kojima, Chiyomaru et al., 2012) , while the up-regulation of ECE1 (Endothelin Converting Enzyme 1) (Smollich, Gotte et al., 2007) , GBP1 (Guanylate Binding Protein 1) (Pedersen, Hood et al., 2017) , HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) (Singh, Yadav et al., 2015) , PARD6A (par-6 family cell polarity regulator alpha) (Viloria-Petit, David et al., 2009 ) is linked to poor outcome and increased metastatic potential in BC.
WDR5 mediates the EMT response to TGFb1
TGFb1 is a pleiotropic cytokine that exerts several different functions in the cell, whose dysregulation mainly impacts on cancer progression and regulation of immune surveillance (David & Massague, 2018) . Since our finding supported that WDR5 is required for EMT, as well as for TGFb1 signaling during BC progression, we treated shLuc and shWDR5 MCF10DCIS cells with recombinant human TGFb1. Then, we tested the relative expression of the mesenchymal genes known to be induced by TGFb1, namely CDH2, TWIST1, SNAI1, SNAI2, ZEB1 (Micalizzi & Ford, 2009) , also showed to be regulated in our PDXs. TGFb1 dramatically increased the expression of these genes without altering WDR5 levels (Appendix Fig. S5A ), while the WDR5 silencing strongly reduced TGFb1-dependent transcription of these targets ( Figure 5A ). As shown in Figure 5B and Appendix Fig. S5B , cell migration was stimulated by TGFb1 and restored to control levels in presence of WDR5 silencing, thus confirming that TGFb1-induced migration and EMT is WDR5 dependent.
Since it has been reported that TGFb1 promotes EMT by a combination of canonical SMAD-dependent and non-canonical SMAD-independent transcriptional events (through the ERK1/2 pathway) (Felipe Lima, Nofech-Mozes et al., 2016), we wanted to confirm whether the TGFb1 downstream mediators SMAD2/3 and ERK1/2 were also prominent for WDR5 regulation of TGFb1 signaling. In our system, SMAD2, but not SMAD3, was phosphorylated by TGFb1, while silencing of WDR5 reduced the phosphorylation of both substrates (Fig. 5C) . Also, phosphorylation of ERK1/2, induced by TGFb1, was inhibited by shWDR5 (Fig. 5D) , thus confirming that various integrated signaling pathways are required for the regulation of WDR5 on TGFb1.
Discussion
A extensive body of literature supports the essential role of WDR5 in targeting histones to epigenetically regulate cancer progression , Ge et al., 2016 , Mungamuri et al., 2013 . TGFb signaling and EMT are strictly interconnected pathways mediated by many key factors including epigenetic and transcriptional regulation (Dumont, Wilson et al., 2008) . In this study we report that WDR5 is an essential gene in breast cancer development and progression that works as a crucial intermediate in coupling TGFb pathway and EMT.
It has been previously shown that WDR5 expression is frequently deregulated in leukemia, colon, pancreatic and prostate cancer , Chen et al., 2015 , Cui et al., 2018 , Ge et al., 2016 . Here, we directly link WDR5 expression to breast cancer progression and metastasis by using a panel of cell lines and PDX models of metastatic breast cancer resistant to different lines of therapy. For these patients offering new therapeutic strategies is mandatory. For in vitro and in vivo studies, we made use of the highly plastic MCF10DCIS breast cancer cell line, known to be able to recapitulate all the stages of breast cancer progression, from in situ growth to metastasis formation (Barnabas & Cohen, 2013 . MCF10DCIS cells appear to be the most attractive model to study the molecular mechanisms responsible of the epigenetic regulation in the transition from the epithelial to the mesenchymal state and viceversa.
WDR5 knockdown was able to reduce tumor growth in LB and TN breast cancers, concordantly with the role of WDR5 in regulating tumorigenesis , Chen et al., 2015 , Mungamuri et al., 2013 . We offered direct evidences of the involvement of WDR5 in breast cancer progression by performing a meta-analysis on metastasis free survival in breast cancer patients, as well as by using in vivo MDA-MB-231 cells and in vitro migratory PDXs.
By employing gene expression profiling of differentially expressed genes in PDXs and breast cancer cell line models, we found that WDR5 transcriptionally regulates an epithelial signature and induce cell adaptation to signaling events. Among these, TGFb regulation is affected by down-modulation of TGFb receptors and downstream targets genes that were reported to control cell migration in tumors (Evensen et al., 2015 , Jaaks & Bernasconi, 2017 , Kojima et al., 2012 , Lu et al., 2017 , Mu et al., 2015 , Pedersen et al., 2017 , Singh et al., 2015 , Smollich et al., 2007 , Tang et al., 2003 , Viloria-Petit et al., 2009 , Wan et al., 2017 , Zhang et al., 2011 (Fig. 6A) . By examining the genome wide WDR5 occupancy, we show that WDR5 directly binds to a subset of gene promoters, among which we highlighted TGFb1, suggesting that WDR5 activates TGFb oncogenic pathways known to be involved in tumorigenesis and metastasis (Felipe Lima et al., 2016) . Indeed, transcriptional regulation of WDR5 targets occurs through recruitment of KMT2A in the COMPASS-like complex, and subsequent methylation of H3K4 (Alicea-Velazquez, Shinsky et al., 2016) .
Our data suggest that a similar mechanism is in place also in breast cancer, as WDR5- In vitro study. Proliferation, migration on Boyden chamber and wound healing assays were performed as described in expanded view.
Immunofluorescence. MCF10DCIS.com cells were infected to silence shLuc or sWDR5 and after two days of infection 1^10 5 cells were plated on slides and allowed to attach overnight. Next day, cells were fixed with 4% paraformaldhehyde for 10 minutes, permeabilized with 0.01% Triton-X and blocked for 1h with 2% bovine serum albumine.
The actin cytoskeleton was stained using FITC-labeled Phalloidin from Sigma (P5282) for 2 hours. Slides were then counterstained with 4',6-diamidino-2-phenylindole (DAPI) for nuclei labelling and mounted on glass slides with Mowiol. Images were collected by motorized Olympus fluorescence microscope at 40X magnification.
Adhesion assay. For adhesion assay, 2^10 4 shLuc and shWDR5 MCF10DCIS.com cells were plated onto different extracellular matrices (collagen -CL, laminin -LM, fibronectin -FN, matrigel -MG). After 1.5 hour, cells were fixed and stained with 0.5% Crystal Violet.
Three images per well were acquired and cell number and area were quantified by using ImageJ software by manually delineating the edges of randomly selected cells (a total of Western blot. PDXs and MCF10DCIS.com cells were lysed in RIPA buffer and processed, as previously described . Membranes were probed with antibodies reported in expanded. Images were cropped at specific protein band of interest to improve the clarity of data presentation.
Survival Analysis. Association between WDR5 expression and metastasis free survival (MFS) in 295 breast cancer patients was calculated using PROGgene V2 software on NKI data sets. MFS were represented by Kaplan-Meier functions and cohorts were divided at the median of gene expression. Statistic comparison between high and low expression groups was performed using log rank test. Differences were considered significant at P < 0.05. ChIP-sequencing. ChIP lysates were generated from 10-15^10 6 cells as reported previously . ChIP DNA was prepared for HiSeq 2000 Illumina sequencing. Samples were aligned to human genome and bioinformatic analysis is fully described in Appendix Supplementary Methods.
RNA-sequencing.
Data Access
Data sets are available in the Gene Expression Omnibus (GEO) database under accession number GSE113289 . MCF10DCIS.com were plated in six-well plates. Drug was added to complete medium at a final concentration of 1µM -5µM -10µM or 20µM for 3 days and cells were then effects on proliferation was assessed. 10 3 cells were plated for colony formation assay and drug was added for 6 days (medium and drug was refreshed on day 3). Cells were then stained with Crystal violet and quantified by ImageJ analysis. Table Legend   Table EV 
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